The Impact of Obesity on T and NK Cells after LVAD Implantation.
Body mass index
Left ventricular assist device
Natural killer cells
Obesity
T cells
Journal
Obesity facts
ISSN: 1662-4033
Titre abrégé: Obes Facts
Pays: Switzerland
ID NLM: 101469429
Informations de publication
Date de publication:
2023
2023
Historique:
received:
13
07
2022
accepted:
06
03
2023
medline:
14
8
2023
pubmed:
26
5
2023
entrez:
26
5
2023
Statut:
ppublish
Résumé
Infections are a major problem after left ventricular assist device (LVAD) implantation that affects morbidity, mortality, and the quality of life. Obesity often increases the risk for infection. In the cohort of LVAD patients, it is unknown if obesity affects the immunological parameters involved in viral defense. Therefore, this study investigated whether overweight or obesity affects immunological parameters such as CD8+ T cells and natural killer (NK) cells. Immune cell subsets of CD8+ T cells and NK cells were compared between normal-weight (BMI 18.5-24.9 kg/m2, n = 17), pre-obese (BMI 25.0-29.9 kg/m2, n = 24), and obese (BMI ≥30 kg/m2, n = 27) patients. Cell subsets and cytokine serum levels were quantified prior to LVAD implantation and at 3, 6, and 12 months after LVAD implantation. At the end of the first postoperative year, obese patients (31.8% ± 2.1%) had a lower proportion of CD8+ T cells than normal-weight patients (42.4% ± 4.1%; p = 0.04), and the percentage of CD8+ T cells was negatively correlated with BMI (p = 0.03; r = -0.329). The proportion of circulating NK cells increased after LVAD implantation patients in normal-weight (p = 0.01) and obese patients (p < 0.01). Patients with pre-obesity showed a delayed increase (p < 0.01) 12 months after LVAD implantation. Further, obese patients showed an increase in the percentage of CD57+ NK cells after 6 and 12 months (p = 0.01) of treatment, higher proportions of CD56bright NK cells (p = 0.01), and lower proportions of CD56dim/neg NK cells (p = 0.03) 3 months after LVAD implantation than normal-weight patients. The proportion of CD56bright NK cells positively correlated with BMI (p < 0.01, r = 0.403) 1 year after LVAD implantation. This study documented that obesity affects CD8+ T cells and subsets of NK cells in patients with LVAD in the first year after LVAD implantation. Lower proportions of CD8+ T cells and CD56dim/neg NK cells and higher proportion of CD56bright NK cells were detected in obese but not in pre-obese and normal-weight LVAD patients during the first year after LVAD implantation. The induced immunological imbalance and phenotypic changes of T and NK cells may influence viral and bacterial immunoreactivity.
Identifiants
pubmed: 37232004
pii: 000530174
doi: 10.1159/000530174
pmc: PMC10427956
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
364-373Informations de copyright
© 2023 The Author(s). Published by S. Karger AG, Basel.
Références
PLoS One. 2014 Jan 17;9(1):e85770
pubmed: 24465695
Annu Rev Immunol. 2008;26:453-79
pubmed: 18062768
J Immunol. 2002 Aug 15;169(4):1984-92
pubmed: 12165524
J Clin Endocrinol Metab. 2011 Dec;96(12):E2018-22
pubmed: 21956416
J Infect Dis. 2019 Apr 19;219(10):1652-1661
pubmed: 30535161
J Obes. 2020 Jan 30;2020:5076858
pubmed: 32089876
J Thorac Dis. 2020 May;12(5):2654-2662
pubmed: 32642173
Front Immunol. 2020 Sep 23;11:573200
pubmed: 33101297
Cancer Immunol Immunother. 2016 Apr;65(4):441-52
pubmed: 26850637
Immunol Res. 2018 Apr;66(2):234-244
pubmed: 29560551
J Thorac Dis. 2017 Nov;9(11):4441-4446
pubmed: 29268513
Clin Infect Dis. 2021 Jan 27;72(2):190-197
pubmed: 31925953
Metabolism. 2007 Jul;56(7):998-1004
pubmed: 17570264
J Heart Lung Transplant. 2019 Apr;38(4):352-363
pubmed: 30945637
Hum Immunol. 2012 May;73(5):480-5
pubmed: 22426256
Am J Gastroenterol. 1996 Nov;91(11):2435-6
pubmed: 8931437
Immun Ageing. 2020 May 27;17:15
pubmed: 32514279
Front Immunol. 2020 Mar 13;11:245
pubmed: 32231659
BMC Pediatr. 2013 Aug 14;13:123
pubmed: 23941335
J Heart Lung Transplant. 2018 Oct;37(10):1207-1217
pubmed: 30195832
Pulm Pharmacol Ther. 2013 Aug;26(4):412-9
pubmed: 22634305
Curr Diab Rep. 2017 Sep;17(9):81
pubmed: 28779366
ASAIO J. 2019 Sep/Oct;65(7):668-673
pubmed: 30198911
Int J Infect Dis. 2013 May;17(5):e348-51
pubmed: 23313155
Clin Exp Immunol. 2014 May;176(2):246-54
pubmed: 24401077
ASAIO J. 2020 Apr;66(4):401-408
pubmed: 31192852
N Engl J Med. 2002 Aug 1;347(5):305-13
pubmed: 12151467
Curr Cardiol Rep. 2018 Sep 26;20(11):117
pubmed: 30259192
Cancers (Basel). 2019 Apr 23;11(4):
pubmed: 31018563
Int J Obes (Lond). 2009 Jan;33(1):151-6
pubmed: 18982006
Exerc Immunol Rev. 2015;21:58-68
pubmed: 25825956
Immunity. 2013 Jan 24;38(1):13-25
pubmed: 23352221
Circ Heart Fail. 2019 Nov;12(11):e006369
pubmed: 31707800
ASAIO J. 2019 Sep/Oct;65(7):678-682
pubmed: 30398982
JCI Insight. 2017 Dec 21;2(24):
pubmed: 29263296
J Exp Med. 1997 Nov 3;186(9):1407-18
pubmed: 9348298
Proc Nutr Soc. 2012 May;71(2):298-306
pubmed: 22414338